Background: Monocytes and macrophages have been shown to play major roles in the progression of atherosclerosis. This study examined whether the circulating monocyte count can be used to predict coronary plaque progression of non-culprit intermediate lesions in acute myocardial infarction (AMI).
he recruitment of circulating monocytes into the arterial wall, followed by their differentiation into tissue macrophages is one of the earliest events in atherosclerotic plaque formation. 1- 5 Increasing evidence suggests that monocytes control smooth muscle cell (SMC) proliferation and migration, 6-9 lipid metabolism, 10 and inflammation 11-14 within the vessel wall. Monocytes have thus been proposed to serve as markers, initiators, and promoters of arterial occlusive diseases. 15, 16 After the onset of acute myocardial infarction (AMI), monocytes are rapidly recruited to the infarcted region, 17,18 where they promote wound healing and extracellular matrix turnover. Monocytes are also recruited to sites of vascular injury after percutaneous coronary intervention (PCI). 19 Fukuda et al 20 have shown that the blood monocyte count increases after elective stent implantation and that the peak monocyte count is associated with the in-stent neointimal volume at the 6-month follow up, suggesting that the recruitment of monocytes around stents might promote migration and proliferation of SMCs as well as neointimal growth.
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Similar phenomena might occur in coronary atherosclerosis. De Lemos et al 21 have shown that elevated plasma levels of monocyte chemoattractant protein-1 (MCP-1), the most important chemokine regulating migration and infiltration of monocytes and macrophages, are associated with an increased risk of death or myocardial infarction (MI) in patients with acute coronary syndromes (ACS). Similar findings were obtained by Kervinen et al, 22 who reported that increased plasma MCP-1 levels were helpful for predicting new coronary events, including death from cardiac causes, recurrent MI, unstable angina, and revascularization during a 13-month follow up, in patients with ACS. Furthermore, MCP-1 expression is upregulated in macrophage-rich areas of human atherosclerotic lesions as compared with non-lesional areas of Monocytes and Coronary Plaque Progression vessels in human carotid endarterectomy specimens. 23 These findings suggest that monocytes have a crucial role in the progression of atherosclerosis after acute coronary events; however, the relationship between the monocyte count and progression of coronary atherosclerosis has not been evaluated prospectively in patients with coronary artery disease. This intravascular ultrasound (IVUS) study was performed to examine the relationship between the circulating monocyte count and coronary plaque progression of non-culprit intermediate lesions during a 7-month follow up after acute coronary events.
Methods

Patient Population
Ninety patients with AMI who were admitted within 24 h from symptom onset were enrolled. All patients received primary PCI to treat culprit lesions. The diagnosis of AMI was based on the presence of continuous chest pain lasting for more than 30 min, ST-segment elevation of greater than 0.2 mV in at least 2 contiguous electrocardiographic leads, and a greater than 2-fold increase in the serum creatine phosphokinase level. Target plaque qualified for the IVUS study if it was unaffected by any previous PCI, if the diameter stenosis was <50% on quantitative coronary angiography, and if the plaque was detected on IVUS. The plaque had to be >10 mm from the PCI site. Patients were excluded if they had cardiogenic shock, collagen disease, advanced liver disease, renal failure, malignancy, or any infectious disease. Hypertension was defined as a previous diagnosis of hypertension or a history of antihypertensive therapy. Dyslipidemia was defined as: a low-density lipoprotein (LDL) cholesterol level of ≥140 mg/dl, high-density lipoprotein (HDL) cholesterol level of <40 mg/dl, fasting triglycerides ≥150 mg/dl, or a history of treatment for dyslipidemia. The protocol for the study was approved by the Ethics Committee of Yokohama City University. Written informed consent was obtained from all participants before coronary angiography and intervention.
PCI Procedure and Antiplatelet Therapy
PCI with or without stent placement and post-PCI management were performed using standard procedures. Intravenous heparin (5,000 IU) and oral aspirin (200 mg) were administered before the procedure. Periprocedural intravenous heparin was given to maintain an activated clotting time of ≥250s. After PCI, all patients received 100 mg aspirin once daily. Patients with stents received 100 mg ticlopidine twice daily (the standard dose in Japan) for at least 4 weeks. Bare metal stents were used in all patients who received stents.
IVUS Examination
For IVUS examinations, the same system (2.9 F, 40-MHz; Boston Scientific) was used at baseline and at the 7-month follow up. All IVUS examinations were performed in the following manner. After careful manipulation of the guidewire and intracoronary administration of 2-3 mg isosorbide dinitrate, the ultrasound catheter was positioned sufficiently distal (>20 mm) to the PCI site. Pullback was performed automatically at 0.5 mm/s. During PCI, IVUS examinations were performed before any balloon inflation or stenting and after PCI. IVUS images were recorded on super VHS videotape and sent to our IVUS laboratory for offline quantitative analysis. Post-PCI images were selected for baseline IVUS analysis.
Angiographic Analysis
Coronary angiograms were reviewed separately by an independent observer blinded to all clinical data and IVUS findings. Quantitative coronary angiography (QCA-CMS, version 4.0; MEDIS Imaging Systems, Leiden, The Netherlands) was used to analyze images of the coronary arterial tree. Standard quantitative measurements 24 were used to calibrate and measure coronary dimensions. Angiographic restenosis was defined as a percent diameter stenosis of >50% at follow up.
IVUS Analysis
Plaque volume was assessed by volumetric analysis with the Netra 3D IVUS system (ScImage, Inc, Los Altos, CA, USA). Baseline coronary angiography and IVUS images were reviewed, and the target segment was selected. One target segment was determined in a non-PCI site (>10 mm proximal or distal to the PCI site) with a reproducible index side branch or stent edge. Segments with an arc of calcification of ≥90° or tortuosity were avoided. Target plaque selection and quantitative analysis were performed by an independent experienced IVUS investigator who was blinded to patient characteristics. Baseline and follow-up IVUS images were reviewed side-by-side on a display, and serial volumetric analysis was performed after intervention and at follow up. At follow up, the target lesions were carefully identified by using at least 3 reproducible landmarks (calcium deposits, side branches, other perivascular structures, and/or stent edge). The target lesion was measured at 1-mm intervals. External elastic membrane (EEM) cross-sectional area (CSA) and lumen CSA were measured. The luminal/intimal borders were traced manually to determine the lumen CSA. The EEM CSA, which represents the area encompassed by the medial/adventitial border, was measured by tracing the leading edge of the adventitia to determine the vessel CSA. Vessel volume and lumen volume were calculated using Simpson's rule. Plaque volume was calculated as vessel volume minus lumen volume. The percent change in plaque volume (%∆PV) was defined as the change in plaque volume (follow up minus baseline plaque volume) divided by the baseline plaque volume. 25 In patients who received stents, the stent site at the 7-month follow up was also investigated to evaluate the association between monocyte count and in-stent neointimal proliferation. Lumen and stent CSA were measured throughout the stented segment at 1-mm intervals. Neointimal CSA was then calculated as the difference between stent and lumen CSA. Lumen, stent, and neointimal volume were calculated with Simpson's method. The neointimal index was calculated as the neointimal volume/stent volume ×100. 26 
Measurement of White Blood Cell (WBC) Count
Peripheral blood samples were obtained from all patients every 6 h until 48 h, every 12 h for the next 3 days, and at the 7-month follow up. Total WBC and WBC fractions were measured with an automated hematology analyzer (XE-2100, Sysmex, Kobe, Japan). Blood sampling was performed carefully and gently to avoid hemolysis.
Definition of Major Adverse Coronary Events
Cardiac events, including death from cardiac causes, MI, or any revascularization (repeated PCI or coronary artery bypass grafting), were recorded.
Statistical Analysis
Statistical analysis was performed with StatView 5.0 software (SAS Institute Inc, Cary, NC, USA). Quantitative data NOZAWA N et al.
are presented as mean ± SD. Paired Student's t-tests were used to compare continuous data from baseline to follow up. Differences between the 2 groups were assessed with the χ2 test for categorical variables and with unpaired the Student's t-test for continuous data. Correlations between %∆PV and WBC fractions were analyzed by linear regression analysis. To determine the optimal cut-off point of the peak monocyte count for the prediction of plaque progression, receiver operating characteristic (ROC) analysis was performed. Multiple logistic analysis was performed to assess the effects of clinical characteristics (ie, male gender, age, classic coronary risk factors, statin use, and peak monocyte count) on the prediction of plaque progression. P values of <0.05 were considered to indicate statistical significance.
Results
Patient Characteristics and Procedural Data
The study group comprised 90 patients. Baseline patient characteristics and medication during follow up are shown in Table 1 . The mean age of the patients was 62.1±9.4 years, and 74 (82%) were men. There were 55 patients with hypertension (61%), 61 with dyslipidemia (68%), and 29 with diabetes mellitus (32%). PCI was successfully performed in all patients. The mean interval from the onset of AMI to arrival at the hospital was 4±4 h. 
Monocytes and Coronary Plaque Progression
Peripheral Monocyte Counts Figure 1 shows the time-course of total WBC and WBC fractions from admission through to the fifth day. Total WBC and neutrophil count reached their peak values within 24 h. In contrast, the mean time from admission to the peak monocyte count was 40±25 h. The lymphocyte count decreased significantly from the value at admission, increased gradually after 6 h, and reached a second peak on the second day. The mean monocyte count at admission was 423±201 /mm 3 and reached a peak value of 855±268 /mm 3 . The mean monocyte count at the 7-month follow up was 316±103 /mm 3 .
Volumetric IVUS Analysis
Follow-up IVUS evaluation was performed at 6.9±1.6 months. The mean target lesion length was 9.9±3.2 mm. Vessel volume, lumen volume, and plaque volume showed no remarkable change from baseline to follow up (212±108 mm 3 to 210±102 mm 3 , P=0.45; 103±58 mm 3 to 103±53 mm 3 , P=0.92; and 109±59 mm 3 to 107±57 mm 3 , P=0.07, respectively). We randomly selected 90 IVUS cross-sectional images from 18 patients to assess the interobserver and intraobserver variabilities for measuring plaque area by 2 independent analysts. The correlation coefficient and mean difference ± SD were 0.97 and 0.19±0.53 mm 2 for the interobserver variability, and 0.98 and 0.11±0.41 mm 2 for the intraobserver variability.
Lipid Profile and Plaque Progression
In the study group as a whole, the LDL cholesterol level de- 
Monocyte Count and Plaque Progression
In the study group as a whole, the peak monocyte count correlated positively with %∆PV (r=0.32, P=0.002); no other WBC fraction correlated with %∆PV (Figure 2) . The peak monocyte count correlated with %∆PV in both patients who received statins during follow up (r=0.32, P=0.02) and in those who did not (r=0.33, P=0.04) (Figure 3) , indicating that this correlation was independent of statin treatment. The monocyte count at admission was not associated with %∆PV (r=0.07, P=0.54), whereas that at discharge was weakly associated with %∆PV (r=0.25, P=0.04). Plaque progression, defined as a %∆PV of >0, occurred in 38 patients (42%). The cut-off point of the peak monocyte count for plaque progression on ROC analysis was 800 /mm 3 . We therefore used 800 /mm 3 as the cut-off point for analyses. 
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This cut-off point yielded a sensitivity of 66% and a specificity of 62% for the detection of plaque progression. We divided the patients into 2 groups according to this cut-off point: 45 patients in the high monocyte group (peak monocyte count ≥800 /mm 3 ) and the other 45 in the low monocyte group (peak monocyte count <800 /mm 3 ). As shown in Figure 4 , there was no difference in the time to peak monocyte count between the high monocyte and the low monocyte groups (42±19 h vs 38±30 h, P=0.51). There was no difference in the frequency of target plaque proximal to the PCI 
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site between the high monocyte group (60%) and the low monocyte group (58%). Multivariate analysis showed that a peak monocyte count of ≥800 /mm 3 was an independent predictor of plaque progression (odds ratio 5.02, 95%CI 1.01-17.89, P=0.005) ( Table 2 ). The high monocyte group had a greater monocyte count as well as a ratio of monocyte-tototal WBC at the 7-month follow up than the low monocyte group (368±109 /mm 3 vs 263±64 /mm 3 , P<0.0001; and 4.9± 1.1% vs 5.7±2.9%, P=0.005, respectively). Both the monocyte count and ratio of monocyte-to-total WBC at the 7-month follow up were associated with %∆PV (r=0.29, P=0.006; r= 0.24, P=0.02, respectively).
QCA and IVUS Analyses for the Culprit Lesion
QCA showed that the high monocyte group had a greater diameter stenosis in the culprit lesion at the 7-month follow up compared with the low monocyte group (45.5±20.2% vs 37.4±12.4%, P=0.03). The frequency of binary restenosis was higher in the high monocyte group than in the low monocyte group (33% vs 16%, P=0.0497). Quantitative IVUS analyses showed that the high monocyte group had a greater neointimal index compared with the low monocyte group in patients who received stents (43.1±13.1% vs 35.6±15.4%, P=0.02).
As expected in this relatively small study, the number of patients with major adverse coronary events during 7 months of follow up did not differ significantly between the high and low monocyte groups (13 patients in the high monocyte group and 6 in the low monocyte group, P=0.07); target lesion revascularization (TLR) for restenosis was performed in 29% (13 of 45) of the high monocyte group and 13% (6 of 45) of the low monocyte group. The frequencies of restenosis and TLR in the high and low monocyte groups are shown in Figure 5 .
Discussion
The present study demonstrated that the circulating monocyte count after AMI was associated with coronary plaque progression. The peak monocyte count was the only significant predictor of plaque progression that was independent of coronary risk factors or statin use. Furthermore, the monocyte count at the 7-month follow up was also associated with plaque progression. In addition, the peak monocyte count was associated with the frequency of restenosis and in-stent neointimal proliferation, as assessed by angiography and IVUS, respectively. During the past decade, monocytes and macrophages have been demonstrated to have an important role in coronary plaque progression. One large study has reported that a high monocyte count in middle-aged healthy men was a predictor of coronary events during 6.6 years of follow up. 27 Among the WBC fractions evaluated, only the monocyte count predicted the risk of coronary events. The rate of coronary events was higher in patients with a monocyte count of >500 /mm 3 than in those with a lower count (hazard ratio 4.6), suggesting that increased numbers of monocytes might have contributed to the development of atherosclerosis or plaque disruption. The monocyte count at baseline was significantly higher in the patients who had coronary events than in those who did not (365±366 vs 227±197 /mm 3 , P<0.001). Interestingly, the monocyte count in patients with future coronary events in their study was similar to that in the high monocyte group at the 7-month follow up in our study. Another study by Chapman et al 28 showed that the monocyte count is an independent predictor of common carotid atherosclerosis in a healthy community population. In our study, a monocyte count of ≥800 mm 3 during the acute phase of AMI correlated with plaque progression in the following months. These findings are supported by the results of several experimental studies. MCP-1 is the most important chemokine regulating the migration and infiltration of monocytes and macrophages and accelerates atherosclerosis in apolipoprotein E-deficient mice. 29 Anti-MCP-1 therapy has been shown not only to attenuate the development of early atherosclerotic lesions, but also to limit progression of pre-existing atherosclerotic lesions in mice, providing further evidence that monocytes play an important role in atherogenesis. 30 A recent study reported that monocytes accumulate continuously during atheroma formation, monocyte accumulation is proportional to lesion size, and monocyte recruitment is augmented by hypercholesterolemia in mice. 31 Recruitment of monocytes into atherogenic foci is required for the onset and progression of atherosclerosis. Kircher et al 32 have demonstrated that monocytes are recruited avidly to plaque within days of an intravenous injection of 111 In-oxine-labeled monocytes using micro-single photo emission computed tomography in live mice. These findings suggest that circulating monocytes might be recruited into atherosclerotic foci without vascular injury. Although several lines of evidence support a pivotal role of monocytes in the progression of atherosclerosis in animal models, a direct link between circulating monocytes and coronary plaque progression has not been verified in humans or primates. To our knowledge, our study is the first to demonstrate a positive correlation between the monocyte count after AMI and coronary plaque progression within a relatively short follow up.
Previous studies have shown that the peripheral monocyte count and monocyte-related cytokine levels are increased in patients with AMI, reflecting the infiltration of monocytes and macrophages into the necrotic myocardium. 33, 34 Although inflammation is a necessary component of the healing process, our findings indicate that peripheral monocytosis during the acute phase of AMI might contribute to coronary plaque progression. A previous study showed that patients with AMI who received immediate invasive treatment had a ≥10% risk of death or non-fatal MI in the following year. 35 In contrast, patients with stable angina seem to have better clinical out- NOZAWA N et al.
comes. In the Swedish Angina Pectoris Aspirin Trial, the rate of death or non-fatal MI was <2% annually. 36 This considerable difference in outcomes suggests that patients with AMI might have several vulnerable plaques leading to recurrent clinical events. Goldstein et al 37 reported that additional multiple complex angiographic lesions are present in 39.5% of patients with AMI, and this subgroup of patients has an increased incidence of recurrent ACS. Rioufol et al 38 performed IVUS interrogation of all 3 coronary trees in patients with ACS and confirmed ≥2 ruptured plaques in up to 79% of patients. These findings suggest that patients with AMI have overall coronary instability, which is responsible for the high recurrence rate even after percutaneous treatment of culprit lesions. Furthermore, Guazzi et al 39 reported rapid progression of coronary plaque in patients with AMI. During an interval of only 1 month, 17 non-culprit lesions in 23 patients with AMI progressed angiographically after the onset of MI, whereas only 2 lesions in 23 patients with stable angina progressed, suggesting that some factor(s) contributes to the rapid progression of atherosclerosis after an index MI. Several studies indicate that neutrophil activation is a marker of widespread inflammation in the coronary vasculature in patients with ACS. 40- 43 Our findings suggest that increased peripheral monocytes after AMI might also contribute to the instability of non-culprit plaque in patients with AMI.
Our results are supported by the findings of a previous study by Fukuda et al, 20 who showed that the peak circulating monocyte count after PCI is associated with in-stent neointimal volume after implantation of bare metal stents. The authors proposed that vascular injury induced by stenting provoked a slight but systemic increase in monocytes (515± 149 /mm 3 ), which might lead to increased monocyte infiltration of vascular tissue around the stent, with monocyte-dependent induction of SMC growth. In our study, greater neointimal hyperplasia was observed in the high monocyte group than in the low monocyte group, confirming their findings. Similar phenomena might occur in native coronary atherosclerosis. In patients with AMI, irreversible myocardial damage caused by coronary occlusion and angioplasty might induce systemic inflammatory responses, including increases in circulating monocytes and monocyte-related cytokines. Increased numbers of circulating monocytes might be recruited into the arterial wall and differentiate into macrophages, leading to foam-cell formation and secretion of several growth factors that promote coronary plaque progression and in-stent neointimal proliferation.
In this study, patients with a peak monocyte count of ≥800 /mm 3 continued to have a high monocyte count even after 7 months of follow up. Although blood monocytes increase in response to tissue or vascular damage, it is very unlikely that the effects of the initial tissue damage caused by AMI persisted for as long as 7 months. We presume that patients with a high monocyte count might have had vascular dysfunction or vascular injury associated with events such as silent plaque rupture (involving coronary, cerebral, or peripheral arteries) during follow up. Vascular injury mobilizes monocytes from bone marrow, and increased numbers of monocytes might accelerate plaque progression and endothelial damage, leading to the vicious circle of persistent monocyte elevation. In contrast, no association was apparent between the monocyte count at admission and coronary plaque progression. Since the time from onset to admission differed among the patients, AMI-induced vascular and myocardial damage might have had a wide range of effects on the monocyte count at admission.
Among several categories of drugs, statins have been most clearly shown to suppress 25 or regress 44-46 coronary atherosclerosis. Lowering of LDL cholesterol is thus considered to play an important part in reducing cardiovascular events. However, one previous study reported that 36 .4% of patients had plaque progression despite intensive lipid-lowering therapy with a mean LDL cholesterol level of 60.8 mg/dl at follow up, suggesting that factors other than LDL cholesterol must be controlled to halt plaque progression completely. 46 In the present study, the monocyte count remained a significant predictor of coronary plaque progression, even after adjusting for dyslipidemia and statin use, suggesting that circulating monocytes might be a useful biomarker for new drug development. In fact, therapeutic strategies that suppress monocyte activation were shown to limit the progression of pre-existing atherosclerotic lesions and stabilize lesion composition in hypercholesterolemic mice. 31 In the present study, patients with and without diabetes had similar %∆PV (-2.0% vs -1.8%, P=0.93). Hemoglobin A1c (HbA1c) significantly improved from baseline to follow up (7.2-6.6%, P=0.03) in diabetic patients (n=29). %∆PV was weakly associated with HbA1c at baseline (r=0.31, P=0.08), but not with that at follow up. Thus, improvement of HbA1c might have attenuated the impact of diabetes on the incidence of plaque progression. Similarly, there was no difference in %∆PV between patients with and without dyslipidemia (-1.8% vs -2.1%, P=0.87). The frequency of statin treatment during follow up was significantly higher in patients with than without dyslipidemia (67% vs 34%, P=0.003). Therefore, greater statin use in patients with dyslipidemia might have attenuated the impact of dyslipidemia on plaque progression.
Study Limitations
Our study had several limitations. It was a single-center retrospective study with a relatively small number of patients. Because we did not perform IVUS in all 3 major coronary arteries and only a portion of the infarct and PCI-related arteries were assessed, our results might have been biased. We did not investigate any monocyte-related chemokines or cytokines. The measurement of factors such as MCP-1, vascular cell adhesion molecule-1 and macrophage-colony stimulating factor would provide significant insight into mechanisms of the association between circulating monocytes and coronary plaque progression. Moreover, the proportion of patients who received statin treatment was relatively low (57%), resulting in a relatively high LDL cholesterol level at the 7-month follow up. However, an association between the maximum monocyte count and plaque progression was evident even in patients given statins, who had a mean LDL cholesterol level of 94.1 mg/dl at follow up.
Conclusion
The present study demonstrated that an increased monocyte count after AMI was associated with coronary plaque progression. Monocyte counts in both the acute phase and at follow up are considered an attractive surrogate biomarker of coronary plaque progression and might be a potential therapeutic target, with the ultimate goal of reducing recurrent cardiovascular events.
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